Document Detail

Inhalation Gases or Gaseous Mediators as Neuroprotectants for Cerebral Ischaemia.
MedLine Citation:
PMID:  23170797     Owner:  NLM     Status:  Publisher    
Ischaemic stroke is one of the leading causes of morbidity and mortality worldwide. While recombinant tissue plasminogen activator can be administered to produce thrombolysis and restore blood flow to the ischaemic brain, therapeutic benefit is only achieved in a fraction of the subset of patients eligible for fibrinolytic intervention. Neuroprotective therapies attempting to restrict the extent of brain injury following cerebral ischaemia have not been successfully translated into the clinic despite overwhelming pre-clinical evidence of neuroprotection. Therefore, an adequate treatment for the majority of acute ischaemic stroke patients remains elusive. In the stroke literature, the use of therapeutic gases has received relatively little attention. Gases such as hyperbaric and normobaric oxygen, xenon, hydrogen, helium and argon all possess biological effects that have shown to be neuroprotective in pre-clinical models of ischaemic stroke. There are significant advantages to using gases including their relative abundance, low cost and feasibility for administration, all of which make them ideal candidates for a translational therapy for stroke. In addition, modulating cellular gaseous mediators including nitric oxide, carbon monoxide, and hydrogen sulphide may be an attractive option for ischaemic stroke therapy. Inhalation of these gaseous mediators can also produce neuroprotection, but this strategy remains to be confirmed as a viable therapy for ischaemic stroke. This review highlights the neuroprotective potential of therapeutic gas therapy and modulation of gaseous mediators for ischaemic stroke. The therapeutic advantages of gaseous therapy offer new promising directions in breaking the translational barrier for ischaemic stroke.
Brad A Sutherland; Joanne C Harrison; Shiva M Nair; Ivan A Sammut
Related Documents :
3675057 - Bubble oxygenation and cardiotomy suction impair the host defense during cardiopulmonar...
24625597 - Magnetic resonance 4d flow reveals unusual hemodynamics associated with aneurysm format...
2127697 - Swine as a model for cardiovascular research: improved cardiopulmonary bypass techniques.
2329827 - Intermittent hypothermic asanguineous cerebral perfusion (cerebroplegia) protects the b...
7736707 - Is allopurinol beneficial in the prevention of renal ischaemia-reperfusion injury in th...
23137187 - Influence of castration on bladder blood flow and function during the rapid phase of an...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-19
Journal Detail:
Title:  Current drug targets     Volume:  -     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Acute Stroke Programme Nuffield, Department of Clinical Medicine, University of Oxford, Level 7, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Minocycline as Cytoprotective Drug: Implications for Therapy of Cerebrovascular and Neurodegenerativ...
Next Document:  Neuroprotection and Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects...